BioInsights - Building from the ground up: business culture learnings for cell and gene therapy biotechs

Building from the ground up: business culture learnings for cell and gene therapy biotechs

Cell & Gene Therapy Insights 2022; 8(1), 15–22

10.18609/cgti.2022.016

Published: 1 February 2022
Interview
James Noble

James Noble (JN) has served as a Non-Executive Director since September 2019. He formerly served as our full-time Chief Executive Officer since March 2014, and part-time CEO from July 2008 to March 2014, and is one of our co-founders. From July 2008 until March 2014, Mr Noble was also CEO of Immunocore. Mr Noble has over 30 years of experience in the biotech industry. He has held numerous non-executive director positions. Mr Noble previously served as Deputy Chairman of GW Pharmaceuticals plc and as a director of CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG and Advanced Medical Solutions plc. Mr Noble is Chairman of Orexo AB and also serves as Chairman of Sutura Therapeutics and as a director of Celleron Therapeutics.Mr Noble qualified as a chartered accountant with Price Waterhouse and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr Noble holds an MA degree from the University of Oxford.